Replies to post #269264 on Amarin Corp Plc (AMRN)

[dukesking]

CBB, I fear that if KDPharma gets approval in Europe for FAP or FDA approval for Covid19 In the US that they will be competing for ReduceIt scripts in the same way that generics will do with the Marine indication. KD is just looking for a way to get their EPA into EU and US markets to compete with Vascepa. All IMO. I may be way off in my worry and would appreciate anyone that can tell me why I’m wrong.